Biotech Values

[dewophile]

VIR (GSK et.al. HBV)

VIR HBV—>48w VIR-2219 +peg-IFN—>31% HBs seroconverion:

Update from EASL

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-presents-new-data-evaluating-potential-vir-1

Data presented in a late-breaker oral presentation from a Phase 2 clinical trial demonstrated that when VIR-2218, an investigational small interfering ribonucleic acid (siRNA), was given for 24 or 48 weeks on top of a course of up to 48 weeks of pegylated interferon alpha (PEG-IFN-?) (cohorts 4 and 5 combined), 16% (5/31) achieved sustained HBsAg loss 24 weeks following the end of treatment.

As you know I had expressed some skepticism regarding that 31% number